EF Hutton Begins Coverage of UroGen Pharma with a “Buy” Rating
On October 14, 2024, EF Hutton announced that it has initiated coverage of UroGen Pharma (LSE:0XOD) with a Buy recommendation.
Fundamentals of Fund Sentiment
Currently, 214 funds or institutions report holdings in UroGen Pharma. This marks a slight increase of one owner, or 0.47%, in the last quarter. The average portfolio weight for these funds in 0XOD is 0.14%, which represents a growth of 15.71%. Over the past three months, total shares held by institutions rose by 46.26%, reaching 40,240K shares.
Rtw Investments holds 3,557K shares of UroGen, constituting 8.45% of the company. This shows an increase from their previous holding of 3,257K shares, amounting to an increase of 8.43%. Rtw has boosted its portfolio allocation in 0XOD by 28.14% in the last quarter.
Adage Capital Partners Gp, L.L.C. owns 3,300K shares, or 7.84% of the firm. Previously, they held 1,300K shares, indicating a significant increase of 60.61%. Their portfolio allocation for 0XOD surged by 178.56% over the past quarter.
Ra Capital Management maintains 3,083K shares, reflecting a 7.32% ownership with no changes since last quarter.
Great Point Partners possesses 2,906K shares, which is equivalent to 6.90% ownership. Their prior record showed ownership of 2,621K shares, marking a 9.83% rise. Overall, Great Point has increased its stake in 0XOD by 52.49% during this period.
Point72 Asset Management holds 2,449K shares, representing 5.82% of UroGen. They reported owning 1,112K shares previously, resulting in a notable increase of 54.60%. This firm has also ramped up its portfolio in 0XOD by 166.03% over the last quarter.
Fintel offers one of the most comprehensive investing research platforms, equipped for individual investors, traders, financial advisors, and small hedge funds. Our data spans global markets and includes fundamentals, analyst reports, ownership data, fund sentiment, options insights, and more. Based on advanced, backtested quantitative models, our exclusive stock picks aim to enhance profitability.
For additional insights, Click to Learn More.
This article initially appeared on Fintel.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
